FDA proposes permanently excluding compounded GLP-1s from 503B outsourcing

Posted by nora_vo2max in Weight Loss & Metabolic - 3 points, 0 comments.

https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s

The FDA is proposing to permanently bar semaglutide, tirzepatide, and liraglutide from compounding under 503B outsourcing facilities. This would effectively end compounded GLP-1 availability for people who can't access brand-name. I've been watching this unfold for a while, my own protocol shifted to brand-name when compounded got too unreliable, but I know a lot of people here rely on compounded versions for cost or access reasons.

The article leaves out whether there's any carve-out for research use or clinical trial exceptions, which matters for a community like this. My question is: if compounding goes fully underground or overseas, does that actually make things safer or just harder to track?

Community discussion - research and educational context only. Not medical advice.